Internal Medicine, Rheumatology · West Hollywood, CA
NPI
1740409283
Since 2007
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
6333 Wilshire Blvd, Suite 200
West Hollywood, CA, 90048
Phone (310) 659-3759
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.2M
60,892 services
Medicare patients, 2024
910
Average age 79
Drug cost, 2024
$4.2M
7,048 prescriptions
Company payments, 2025
$3,719
From 27 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Karen M Shainsky was code J3304 (injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg), 26,962 times for 422 patients. In total Karen M Shainsky billed 60,892 services in 36 codes, and Medicare paid $1.2M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2014-10-16.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| J3304 Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg | Office | 26,962 | 422 | $13.76 | $371K |
| J0897 Injection, denosumab, 1 mg | Office | 11,100 | 140 | $15.80 | $175K |
| J7320 Hyaluronan or derivitive, genvisc 850, for intra-articular injection, 1 mg | Office | 10,250 | 73 | $4.30 | $44K |
| J7332 Hyaluronan or derivative, triluron, for intra-articular injection, 1 mg | Office | 2,845 | 31 | $8.06 | $23K |
| 99214 Office E&M - Established | Office | 2,467 | 816 | $117.85 | $291K |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 1,595 | 244 | $0.76 | $1,215 |
| 20610 Joint Injection | Office | 1,367 | 390 | $60.08 | $82K |
| 76942 Ultrasound - Nonspecific | Office | 1,301 | 432 | $54.24 | $71K |
| 99212 Office E&M - Established | Office | 830 | 265 | $53.17 | $44K |
| 96372 Injection Administration | Office | 373 | 216 | $13.40 | $4,997 |
| 36415 Venipuncture Blood Collection | Office | 366 | 263 | $8.65 | $3,166 |
| 99205 Office E&M - New | Office | 182 | 182 | $200.03 | $36K |
| 20553 Musculoskeletal | Office | 153 | 108 | $53.40 | $8,170 |
| 20605 Joint Injection | Office | 129 | 92 | $51.62 | $6,659 |
| 96413 Chemotherapy Administration | Office | 94 | 19 | $125.27 | $12K |
By year: 2022 $899K for 30,824 services; 2023 $965K for 45,143 services; 2024 $1.2M for 60,892 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 366 | 263 | $8.65 | $3,166 |
Medicare prescription drug claims, 2024
In 2024, the drug Karen M Shainsky prescribed most often to Medicare patients was Gabapentin, with 855 prescriptions and refills. In total Karen M Shainsky wrote 7,048 Medicare prescriptions that cost $4.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Gabapentin Generic | 855 | 874 | 133 | $2,999 |
| Diclofenac Sodium Generic | 614 | 619 | 86 | $368K |
| Lidocaine Generic | 421 | 435 | 53 | $62K |
| Tramadol Hcl Generic | 382 | 387 | 76 | $1,072 |
| Methotrexate Methotrexate Sodium | 312 | 341 | 33 | $3,433 |
| Prolia Denosumab | 308 | 1,848 | 185 | $508K |
| Colchicine Generic | 260 | 276 | 29 | $4,812 |
| Diclofenac Epolamine Generic | 253 | 256 | 33 | $150K |
| Hydroxychloroquine Sulfate Generic | 210 | 237 | 30 | $3,814 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 187 | 187 | 47 | $2,779 |
| Meloxicam Generic | 137 | 143 | 33 | $243 |
| Mounjaro Tirzepatide | 123 | 133 | 21 | $133K |
| Prednisone Generic | 114 | 115 | 18 | $414 |
| Pregabalin Generic | 110 | 110 | Under 11 | $444 |
| Celecoxib Generic | 110 | 110 | 20 | $1,274 |
Brand drugs: - claims; generic drugs: 5,269 claims; opioid claims: 695.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Karen M Shainsky $3,719 ($3,719 in general payments such as food, travel and fees) from 27 companies. The largest payer was Amgen Inc. with $628.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 29 | $628 |
| Abbvie Inc. ABBV | 24 | $535 |
| Novartis Pharmaceuticals Corporation NVS | 17 | $380 |
| Radius Health, Inc. | 11 | $293 |
| UCB, Inc. UCB.BR | 7 | $223 |
| ANI Pharmaceuticals, Inc. ANIP | 7 | $193 |
| GlaxoSmithKline, LLC. GSK | 10 | $188 |
| Pfizer Inc. PFE | 6 | $150 |
| IBSA Pharma Inc. | 8 | $141 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 5 | $132 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.